文献速递重症综合管理与镇静镇痛

夜间小剂量右美托咪定预防ICU谵妄:一项随机安慰剂对照试验

Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01
一句话结论两中心双盲RCT显示,夜间静脉输注小剂量右美托咪定可使ICU无谵妄比例从54%升至80%,患者自评睡眠质量未见改变。

这项两中心、双盲、安慰剂对照试验纳入100例无谵妄且正在接受镇静的危重症成人,随机接受夜间(晚9:30至早6:15)静脉右美托咪定(0.2 μg/kg/h起始,每15分钟滴定0.1 μg/kg/h至目标RASS -1或最大0.7 μg/kg/h)或安慰剂直至ICU出院,研究输注期间所有镇静药减半、阿片类不变。谵妄用ICU谵妄筛查清单每12小时评估一次。右美托咪定组ICU期间保持无谵妄的比例为80%(40/50),安慰剂组为54%(27/50),相对危险度0.44(95%CI 0.23-0.82,P=0.006)。两组Leeds睡眠评估问卷平均分相似(均差0.02,95%CI 0.42-1.92),低血压、心动过缓或两者兼有的发生率无显著差异。

要点

  • 夜间小剂量右美托咪定组ICU期间无谵妄比例为80%(40/50),安慰剂组为54%(27/50),相对危险度0.44(95%CI 0.23-0.82,P=0.006)。
  • 给药方案为夜间(晚9:30至早6:15)静脉输注,起始0.2 μg/kg/h,每15分钟滴定0.1 μg/kg/h至目标RASS -1或最大0.7 μg/kg/h,持续至ICU出院。
  • 研究输注期间所有镇静药减半、阿片类药物不变。
  • 可提供至少一次睡眠评估的患者中,右美托咪定组34例(人均约7次评估)与安慰剂组30例(人均约6次评估)的Leeds睡眠评估问卷平均分相似(均差0.02,95%CI 0.42-1.92)。
  • 低血压、心动过缓或两者兼有的发生率两组无显著差异。

适用人群与场景

  • 两中心、双盲、安慰剂对照试验纳入的100例无谵妄、正在接受镇静的危重症成人。

诊断标准与关键阈值

  • 谵妄评估采用ICU谵妄筛查清单(Intensive Care Delirium Screening Checklist),整个ICU住院期间每12小时评估一次。
  • 镇静目标为Richmond躁动-镇静评分(RASS)-1。

处置流程与药物剂量

  • 夜间(晚9:30至早6:15)静脉输注右美托咪定,起始0.2 μg/kg/h,每15分钟滴定0.1 μg/kg/h直至目标RASS -1或最大速率0.7 μg/kg/h,持续至ICU出院。
  • 研究输注期间所有镇静药减半,阿片类药物不变。

研究设计与关键结果

  • 研究类型为两中心、双盲、安慰剂对照试验,样本量100例无谵妄的接受镇静的危重症成人。
  • 主要终点:右美托咪定组ICU期间保持无谵妄40/50(80%),安慰剂组27/50(54%),相对危险度0.44(95%CI 0.23-0.82,P=0.006)。
  • 睡眠:能提供至少一次评估的患者中,右美托咪定组34例(人均约7次评估)与安慰剂组30例(人均约6次评估)的Leeds睡眠评估问卷平均分均差0.02(95%CI 0.42-1.92)。
  • 不良事件:低血压、心动过缓或两者兼有的发生率两组无显著差异。

证据类型、等级与局限

  • 证据类型为随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于正在接受镇静的无谵妄危重症成人,作者结论认为夜间给予小剂量右美托咪定可降低ICU期间谵妄发生率,患者自评睡眠质量似乎未见改变。

指南或共识出处

  • 临床试验注册号NCT01791296。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Dexmedetomidine is associated with less delirium than benzodiazepines and better sleep architecture than either benzodiazepines or propofol; its effect on delirium and sleep when administered at night to patients requiring sedation remains unclear.

OBJECTIVES: To determine if nocturnal dexmedetomidine prevents delirium and improves sleep in critically ill adults.

METHODS: This two-center, double-blind, placebo-controlled trial randomized 100 delirium-free critically ill adults receiving sedatives to receive nocturnal (9:30 p.m. to 6:15 a.m.) intravenous dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg /kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h was reached) or placebo until ICU discharge. During study infusions, all sedatives were halved; opioids were unchanged. Delirium was assessed using the Intensive Care Delirium Screening Checklist every 12 hours throughout the ICU admission. Sleep was evaluated each morning by the Leeds Sleep Evaluation Questionnaire.

MEASUREMENTS AND MAIN RESULTS: Nocturnal dexmedetomidine (vs. placebo) was associated with a greater proportion of patients who remained delirium-free during the ICU stay (dexmedetomidine [40 (80%) of 50 patients] vs. placebo [27 (54%) of 50 patients]; relative risk, 0.44; 95% confidence interval, 0.23-0.82; P = 0.006). The average Leeds Sleep Evaluation Questionnaire score was similar (mean difference, 0.02; 95% confidence interval, 0.42-1.92) between the 34 dexmedetomidine (average seven assessments per patient) and 30 placebo (six per patient) group patients able to provide one or more assessments. Incidence of hypotension, bradycardia, or both did not differ significantly between groups.

CONCLUSIONS: Nocturnal administration of low-dose dexmedetomidine in critically ill adults reduces the incidence of delirium during the ICU stay; patient-reported sleep quality appears unchanged. Clinical trial registered with www.clinicaltrials.gov (NCT01791296).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Skrobik Y, Duprey MS, Hill NS, et al. Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2018. PMID: 29498534. doi:10.1164/rccm.201710-1995OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。